Azurrx Biopharma Inc (AZRX) Forecast, Price Target & Analyst Ratings

NASDAQ:AZRX

Current stock price

3.45
+0.07 (+2.07%)
At close:
3.42
-0.03 (-0.87%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for Azurrx Biopharma Inc (AZRX).

Forecast Snapshot

Consensus Price Target

Price Target
$3.40
-1.45% Downside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
N/A
Period
Q3 / 2021
EPS Estimate
-$0.08
Revenue Estimate
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
90.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$3.40
Upside
-1.45%
From current price of $3.45 to mean target of $3.40, Based on 4 analyst forecasts
Low
$2.02
Median
$3.06
High
$5.25

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

4 Wall Street analysts provided a forecast for the next 12 months for AZRX. The average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

AZRX Current Analyst RatingAZRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5

Analyst Ratings History

AZRX Historical Analyst RatingsAZRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 1 2 3 4

Analyst Ratings Consensus

ChartMill Buy Consensus
90.00%
AZRX was analyzed by 4 analysts. The buy percentage consensus is at 90. So analysts seem to be very confident about AZRX.
In the previous month the buy percentage consensus was at a similar level.
Only 4 analysts analyzed AZRX. So this is just the average opinion of a couple of analysts.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2021-08-02HC Wainwright & Co.Maintains Buy
2021-04-01Roth CapitalMaintains Buy
2021-04-01HC Wainwright & Co.Maintains Buy
2021-02-10HC Wainwright & Co.Maintains Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A
Period
Q3 / 2021
EPS Estimate
-$0.08
Revenue Estimate
Revenue Q2Q
N/A
EPS Q2Q
55.00%
Number of Analysts
6

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2021 - 2025

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
AZRX revenue by date.AZRX revenue by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/A
3.45%		N/A
5.00%
EBITDA
YoY % growth
AZRX ebitda by date.AZRX ebitda by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
AZRX ebit by date.AZRX ebit by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Operating Margin
AZRX operating margin by date.AZRX operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
AZRX eps by date.AZRX eps by date.
N/A-1.05
65.10%		-0.90
14.29%		-0.73
19.07%		-0.85
-16.69%		N/A
52.24%		N/A
27.76%		N/A
28.10%		N/A
-25.43%		N/A

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q3 / 21 Q4 / 21 Q1 / 22 Q2 / 22 Q3 / 22 Q4 / 22
EPS
Q2Q % growth		-0.08
55.00%		-0.08
75.32%		-0.07
49.00%		-0.06
61.75%		-0.06
20.00%		-0.06
20.00%
Revenue
Q2Q % growth		N/AN/AN/A
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		N/AN/AN/AN/AN/AN/A

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

AZRX Yearly Revenue VS EstimatesAZRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 5M 10M 15M
AZRX Yearly EPS VS EstimatesAZRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
20.55%
EPS Next 5 Year
11.05%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

Azurrx Biopharma Inc / AZRX Forecast FAQ

Can you provide the average price target for Azurrx Biopharma Inc stock?

4 analysts have analysed AZRX and the average price target is 3.4 null. This implies a price decrease of -1.45% is expected in the next year compared to the current price of 3.45.

Can you provide the consensus estimates for Azurrx Biopharma Inc next earnings?

The consensus EPS estimate for the next earnings of Azurrx Biopharma Inc (AZRX) is -0.08 null and the consensus revenue estimate is 0 null.

Can you provide the analyst count for Azurrx Biopharma Inc stock?

The number of analysts covering Azurrx Biopharma Inc (AZRX) is 4.